相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Rentschler Biopharma SE has appointed Dr. Torsten Wöhr as Chief Executive Officer, effective August 1, 2026, succeeding interim CEO Prof. Dr. Uwe Buecheler. - Dr. Wöhr brings over 25 years of international CDMO and biotechnology experience, most recently serving as Chief Commercial Officer at Bachem Group. - The appointment marks the next phase of the company's corporate strategy focused on long-term growth and sustainable value creation. - Prof. Dr. Uwe Buecheler will step down as interim CEO and resume his role as Vice Chairman of the Supervisory Board.
- The global fill-finish manufacturing market reached roughly US$11 billion in 2025, with more than US$27 billion committed to expanding sterile capacity across 2024–2025 alone. - The GLP-1 boom has displaced non-GLP-1 sterile products from existing filling lines, forcing sponsors of antibodies, vaccines, and specialty injectables to seek new manufacturing partners. - Asia-Pacific is building isolator-first, device-aware fill-finish capacity faster than any other region, though equipment qualification lead times of 12–18 months mean most expansions will not be operational until 2027–2028. - The revised EU GMP Annex 1 has raised the regulatory floor globally, making the Contamination Control Strategy a mandatory, inspection-ready system that directly constrains throughput and batch risk.
- The US pharmaceutical excipients market is projected to grow from USD 3.08 billion in 2025 to USD 5.58 billion by 2035, at a CAGR of 6.12%. - Fillers and diluents held the largest market share in 2025, while coating agents are expected to be the fastest-growing functionality segment. - Lactose-based excipients dominated by type in 2025, with cellulose-based excipients poised for the highest growth rate through 2035. - New Jersey leads the US market due to concentrated pharmaceutical manufacturing and research infrastructure in the state.
